Investor Relations

Investor Relations

Dynavax Overview

Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], a hepatitis B vaccine for adults, is approved in the United States.

Upcoming Events

Nov 20, 2019
at 9:45 AM EST